About Quest Diagnostics Inc
- Industry: Health Care
- Exchange: NEW YORK STOCK EXCHANGE, INC.
- Country: US
- Website: https://www.questdiagnostics.com/
Frequently Asked Questions
What is the 52-week range for DGX?
The 52-week high is $248.84 and the 52-week low is $171.18.
What is the P/E ratio for DGX?
The Price to Earnings (P/E) ratio is 24.08.
What is the dividend yield for DGX?
The indicated annual dividend yield is 2.10%.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is 14.49%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is 9.19%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 2.69.
Analyst Recommendation Trends
Wall Street analyst consensus for DGX over the last few months:
Latest DGX News
Dividend Champion, Contender, And Challenger Highlights: Week October 4
Track weekly dividend updates for Dividend Champions, Contenders & Challengersâsee dividend changes, upcoming ex-dividend and pay dates. Read it here.
Quest Diagnostics (NYSE:DGX) Breakout Setup Backed by Technical Rating 7 and Setup Rating 8
Quest Diagnostics (DGX) scores 7 for trend and 8 for setup, with a defined breakout entry above 237.95 and support near 230.87.
Apple Is Betting Improved Heart and Health Insights Will Boost Watch Sales
Like runners striving to break from the pack, a slew of wearables companies are competing for share of consumers’ health and fitness tracking habits. With Apple latest heart-rate focused updates to its best-selling Apple Watch and an upcoming Health app redesign, it’s hoping to expand an already impressive lead. Users will be able to calculate their “health age”—a comparison of their overall health measurements with their actual age—as well as a Readiness score that gauges capacity for strenuous activity.
Apple’s Betting Improved Heart and Health Insights Will Boost Watch Sales
Like runners striving to break from the pack, a slew of wearables companies are competing for share of consumers’ health and fitness tracking habits. With Apple latest heart-rate focused updates to its best-selling Apple Watch and an upcoming Health app redesign, it’s hoping to expand an already impressive lead. Users will be able to calculate their “health age”—a comparison of their overall health measurements with their actual age—as well as a Readiness score that gauges capacity for strenuous activity.
Haystack MRD® Demonstrates Robust Clinical Performance in Specimen Cohort from the Landmark DYNAMIC Colorectal Cancer Trials
A new study published in The Journal of Molecular Diagnostics showed that the Haystack MRD® test is highly accurate at detecting residual and recurrent disease, demonstrating clinical performance in specimens from the landmark DYNAMIC colorectal cancer trial series. The study also validated the test’s analytical performance across 23 solid tumor types. Provided by Quest Diagnostics (NYSE: DGX), Haystack MRD is an ultrasensitive circulating tumor DNA (ctDNA) liquid biopsy test for identifying res
Who We Play For and Myelai Launch Heart Screening Program at Quest Diagnostics in Tampa as Florida Becomes First State to Require ECGs for High School Athletes
Who We Play For, a nonprofit that championed Florida's Second Chance Act, Myelai, and Unless Health today announce the launch of a cardiac screening program at Quest Diagnostics' Sheldon Road location in Tampa, giving families a fast way to complete the electrocardiogram (ECG) heart screening now required for Florida high school athletes.
Quest Diagnostics Stock Gains 36.3% YTD: What's Behind the Rally?
DGX's 36.3% YTD rise reflects momentum in advanced diagnostics, channel growth, AI adoption and cost savings.
Quest Diagnostics (DGX) Could Be 5% Below Fair Value After Apple Health Launch
Quest Diagnostics (DGX) drew fresh attention after announcing an Apple Health integration that allows iPhone and iPad users to order a preventive lab panel with more than 50 biomarkers for US$119. The Apple Health tie-in lands after a strong run in Quest Diagnostics’ shares, with the price up 15.6% over 90 days and 35.1% year to date, even though the last month’s share price return slipped 3.9% as traders reassessed shorter term risk and reward. Scan beyond Quest Diagnostics and see how other...
Quest Diagnostics Incorporated: Testing Growth Keeps Me Bullish Despite Medicare Headwinds
Quest Diagnostics outlook: recurring testing demand & acquisitions support growth via hospital partnerships, dialysis & advanced diagnostics. More on DGX stock.
Quest Diagnostics (DGX) Stock Could Be 30% Below Fair Value Following Medicare Payment Cut Concerns
Quest Diagnostics has delivered a strong run in recent years, which raises a straightforward question for investors who care about fundamentals. Is the current share price still aligned with the cash the business is expected to generate over time, or has sentiment moved ahead of its underlying economics? Over the past 3 years, Quest Diagnostics has returned 108.9%, which puts real weight on whether that gain is grounded in durable cash flows rather than just multiple expansion. A recent...
Quest Diagnostics to Release Third Quarter Financial Results on October 22, 2026
Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced today that it will report its third quarter 2026 financial results on Thursday, October 22, 2026, before the market opens. It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Time on that day.
Stock Market Today: Dow Skids As Trump Threatens Iran; Medical Diagnostics Plays Swoon (Live Coverage)
Stock Market Today: The Dow Jones index was lower after President Trump threatened Iran at the UN. Apple stock is near a buy point.
These S&P500 stocks have an unusual volume in today's session
Let's take a closer look at the S&P500 stocks with an unusual volume in today's session on Tuesday. Stay informed about the market activity below.
These S&P500 stocks are moving in today's session
Get insights into the S&P500 index performance on Tuesday. Explore the top gainers and losers within the S&P500 index in today's session.
Why Quest Diagnostics Holdings Stock Dropped Today
The government thinks it's been overpaying Quest Diagnostics. They plan to stop doing that next year.
NICU Genetic Testing Market Size, Share & Trends Analysis - Global Opportunity Analysis and Industry Forecast (2026-2036)
The global NICU genetic testing market is forecast to grow from USD 1.74 billion in 2026 to USD 4.80 billion by 2036, at a 10.67% CAGR. Growth is driven by rising neonatal genetic disorders, rapid whole genome and exome sequencing, next-generation sequencing, chromosomal microarrays and personalized neonatal care. North America leads the market, while Asia-Pacific is expected to grow fastest. The report analyzes key trends, technologies, segments, regional opportunities and leading companies, in
What's going on in today's session: S&P500 gap up and gap down stocks
Curious about the S&P500 stocks that are gapping on Tuesday? Explore the gap up and gap down stocks in the S&P500 index during today's session.
Quest Diagnostics Study Finds High Tick-Borne Disease Co-Exposure
DGX study finds nearly one-third of Lyme-seropositive patients had antibodies to another tick-borne pathogen, highlighting broader testing needs.
Quest Diagnostics, Labcorp Shares Fall as Medicare Signals Cuts in Payment Rates for Lab Services
Quest Diagnostics (DGX) and Labcorp (LH) shares fell in Tuesday premarket trading after the Centers
Discover the top S&P500 movers in Tuesday's pre-market session.
Get insights into the top gainers and losers in the S&P500 index of Tuesday's pre-market session.
Is This the Right Time to Add DGX Stock to Your Portfolio?
Quest Diagnostics gains momentum from customer wins, advanced diagnostics and AI initiatives, while reimbursement uncertainty, costs and debt pose challenges.
Stocks making the biggest moves midday: Lennar, Capri, Vicor, Amgen & more
These are the stocks posting the largest moves midday.
Is Quest Diagnostics Stock Outperforming the Nasdaq?
Quest Diagnostics has outperformed the Nasdaq over the past year, and analysts are moderately optimistic about the stock’s prospects.
Premarket movers: Quest, Labcorp hit by CMS cuts
Investing.com - U.S. stock index futures steadied on Tuesday, following a strong session on Wall Street that saw the benchmark S&P 500 post its best day since August, helped by gains in artificial intelligence-linked stocks.
CMS Targets $1 Billion in Annual Savings With new Medicare Lab Payment Rates — Here’s What Could Change in 2027
CMS proposes 2027 Medicare lab rates, estimating $1 billion in annual taxpayer savings as payments align with private rates.
Ericsson, Lexeo Therapeutics And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session
U.S. stock futures were mixed. Ericsson fell 4.3% after a Morgan Stanley downgrade; Quest Diagnostics, Rambus and others also declined premarket.
Stocks making the biggest moves premarket: Alibaba, Quest Diagnostics, On Holding, GameStop & more
These are the stocks posting the largest moves in early trading.
Why Vicor Shares Are Trading Higher By Over 11%; Here Are 20 Stocks Moving Premarket
Vicor jumped 11% premarket after raising Q3 growth guidance above 20%; TOPS, FBGL and QNME led other gainers.
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Milestone Scientific (AMEX:MLSS) stock moved upwards by 11.8% to $0.44 during Monday's after-market session. The company's market cap stands at $36.9 million. Evotec (NASDAQ:EVO) stock rose 8.44% to
Quest Diagnostics Sees Growth Outpace Targets as Consumer Testing Surges
Quest Diagnostics (NYSE:DGX) CEO and President Jim Davis said the diagnostic testing company is exceeding the growth framework it outlined at its prior investor day, driven largely by organic growth, consumer-health demand and partnerships rather than a heavier-than-expected pace of acquisitions. D
Beat the Market Like Zacks: PBF, Palantir, Adobe in Focus
Market uncertainty persists, but Zacks highlights strong gains across key portfolios and stocks, including PBF, PLTR and ADBE
Nearly 1 in 3 Patients with Suspected Lyme Disease are Co-Positive for Other Tick-Borne Pathogens, Finds Study by Quest Diagnostics
Nearly one in three patients found to have antibodies against the bacterium that causes Lyme disease also had antibodies against one or more additional tick-borne pathogens, according to a new study by researchers from Quest Diagnostics (NYSE: DGX) and the University of North Carolina at Chapel Hill.
Truist Securities Maintains Hold on Quest Diagnostics, Raises Price Target to $260
Truist Securities analyst David Macdonald maintains Quest Diagnostics (NYSE:DGX) with a Hold and raises the price target from $250 to $260.
Quest Diagnostics Study Indicates That Nearly One In Three Patients With Antibodies Against Bacterium That Causes Lyme Disease Also Had Antibodies Against One Or More Additional Tick-Borne Pathogens
New study by researchers from Quest Diagnostics (NYSE:DGX) and the University of North Carolina at Chapel Hill. Published in JAMA Network Open, the study, titled "Coseropositivity to Tick-Borne Pathogens Among
Fed Hikes Interest Rates, Signals Another: 4 Low-Beta Defensive Picks
Fed hikes rates and signals another, putting MGEE, ADM, DOLE and DGX in focus as low-beta defensive picks.
Quest Diagnostics Incorporated (DGX) Hits Fresh High: Is There Still Room to Run?
Quest Diagnostics (DGX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Nine in 10 Voters Express Concern That Medicare Lab Payment Cuts Will Harm Patient Access to Diagnostic Lab Testing, Finds National Survey from Quest Diagnostics
A new national survey finds the overwhelming majority of American voters rely on diagnostic laboratory testing to guide their healthcare decisions and are deeply concerned about scheduled Medicare payment cuts that could put that access at risk.
Discover which S&P500 stocks are making waves on Tuesday.
Curious about the S&P500 stocks that are in motion on Tuesday? Join us as we explore the top movers within the S&P500 index during today's session.
Quest Diagnostics Incorporated (DGX) Presents at 2026 Global Healthcare Conference Transcript
Quest Diagnostics Incorporated (DGX) 2026 Global Healthcare Conference September 15, 2026 10:50 AM EDTCompany ParticipantsJames Davis - Chairman, CEO &...
10-Year Yield Tops 5%, Oil Storms Past $105: Stock Market Today
The 10-year Treasury yield broke 5% for the first time since 2007 as WTI surged past $105 on Saudi pipeline outages, pressuring stocks ahead of the Fed.
Quest Diagnostics Incorporated (DGX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Quest Diagnostics Incorporated (DGX) Morgan Stanley 24th Annual Global Healthcare Conference September 14, 2026 10:00 AM EDTCompany ParticipantsSam Samad -...
Apple Health app Users to be Able to Order Labs from Quest Diagnostics
Quest Diagnostics (NYSE: DGX) today announced that Apple Health app users in the United States1 will be able to conveniently purchase a tailored Quest laboratory test panel that includes over 50 biomarkers directly through the app on iPhone and iPad later this year. Apple first announced the upcoming update today at its September event.
Quest Diagnostics CEO Sells 10,000 Shares for $2.4 Million
J. E. Davis disposed of 8% of his direct equity stake under a pre-planned Rule 10b5-1 trading arrangement, retaining $28.9 million in company stock.
UBS Maintains Neutral on Quest Diagnostics, Raises Price Target to $245
UBS analyst Kevin Caliendo maintains Quest Diagnostics (NYSE:DGX) with a Neutral and raises the price target from $232 to $245.
Could Roche and Lilly’s Blood Test Make Alzheimer’s Assessment More Accessible?
Testing for Alzheimer’s-related brain changes has traditionally depended on procedures that can be expensive, invasive, or difficult to access. Roche Holding AG and Eli Lilly and Company (NYSE:LLY) may now have a simpler way to help physicians evaluate certain patients. The FDA has cleared Elecsys pTau217, which is a blood test that helps identify whether […]
Clinical Laboratory Services Market Size, Share & Trends Analysis - Global Opportunity Analysis & Industry Forecast (2026-2036)
The global clinical laboratory services market was valued at USD 274.6 billion in 2025 and is forecast to reach USD 468.2 billion by 2036, rising from USD 298.4 billion in 2026 at a 4.6% CAGR. Growth is driven by chronic diseases, preventive healthcare, molecular diagnostics, genomic testing, precision medicine, laboratory automation, AI-enabled diagnostics, and at-home testing. North America leads, while Asia-Pacific is set for the fastest growth. The report analyzes key segments, regions, oppo
Quest’s Expanded Alzheimer’s and Wellness Testing Push Might Change The Case For Investing In DGX
In recent months, Renalytix PLC, Humanity Health Inc., and Quest Diagnostics have announced new collaborations and product launches, including a nationwide kidneyintelX.dkd testing program, a Humanity Biological Age wellness add-on on questhealth.com, and expanded AD-Detect blood-based Alzheimer’s tests accessible through Quest’s U.S. collection network. Together, these moves highlight Quest’s push to deepen its role in advanced kidney, brain health, and consumer-oriented wellness testing...
Why Is DaVita HealthCare (DVA) Down 4.9% Since Last Earnings Report?
DaVita HealthCare (DVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-09-01 | Davis J. E. | -10,000 | $242.72 | $2,427,200 |
| 2026-08-28 | PREVOZNIK MICHAEL E | -22,677 | $112.17 | $2,543,679 |
| 2026-08-28 | PREVOZNIK MICHAEL E | -1,000 | - | - |
| 2026-08-28 | PREVOZNIK MICHAEL E | -430 | $244.5148 | $105,141 |
| 2026-08-28 | PREVOZNIK MICHAEL E | -6,237 | $243.6275 | $1,519,505 |
| 2026-08-28 | PREVOZNIK MICHAEL E | -16,010 | $242.8755 | $3,888,437 |
| 2026-08-28 | PREVOZNIK MICHAEL E | +22,677 | $112.17 | $2,543,679 |
| 2026-07-28 | DELANEY MARK E | -1,600 | $235.18 | $376,288 |
| 2026-07-22 | KUPPUSAMY KARTHIK | +37 | $206.807 | $7,652 |
| 2026-07-22 | CARTER ROBERT B | +11 | $206.804 | $2,275 |
| 2026-07-22 | Gregg Vicky B | +72 | $206.808 | $14,890 |
| 2026-07-22 | Plewman Patrick | +46 | $206.807 | $9,513 |
| 2026-07-22 | MAIN TIMOTHY L | +21 | $206.81 | $4,343 |
| 2026-07-22 | SAMAD SAM | +102 | $206.807 | $21,094 |
| 2026-07-22 | Lassiter Wright III | +6 | $206.813 | $1,241 |
| 2026-07-22 | DELANEY MARK E | +34 | $206.807 | $7,031 |
| 2026-07-01 | WENTWORTH TIMOTHY C | +144 | - | - |
| 2026-06-04 | KUPPUSAMY KARTHIK | -4,827 | $121.805 | $587,953 |
| 2026-06-04 | KUPPUSAMY KARTHIK | -3,320 | $127.725 | $424,047 |
| 2026-06-04 | KUPPUSAMY KARTHIK | -8,147 | $200 | $1,629,400 |
| 2026-06-04 | KUPPUSAMY KARTHIK | +4,827 | $121.805 | $587,953 |
| 2026-06-04 | KUPPUSAMY KARTHIK | +3,320 | $127.725 | $424,047 |
| 2026-06-01 | Davis J. E. | -10,000 | $194.14 | $1,941,400 |
| 2026-05-20 | Lassiter Wright III | +1,142 | - | - |
| 2026-05-20 | Diaz Luis | +1,142 | - | - |
| 2026-05-20 | Doi Tracey | +1,142 | - | - |
| 2026-05-20 | Gregg Vicky B | +1,142 | - | - |
| 2026-05-20 | WENTWORTH TIMOTHY C | +1,142 | - | - |
| 2026-05-20 | MORRISON DENISE M | +1,142 | - | - |
| 2026-05-20 | RING TIMOTHY M | +1,142 | - | - |
| 2026-05-20 | CARTER ROBERT B | +1,142 | - | - |
| 2026-05-20 | MAIN TIMOTHY L | +1,142 | - | - |
| 2026-05-20 | PFEIFFER GARY M | +1,142 | - | - |
| 2026-04-20 | SAMAD SAM | +108 | $194.698 | $21,027 |
| 2026-04-20 | Plewman Patrick | +49 | $194.699 | $9,540 |
| 2026-04-20 | Gregg Vicky B | +68 | $194.698 | $13,239 |
| 2026-04-20 | CARTER ROBERT B | +7 | $194.699 | $1,363 |
| 2026-04-20 | Lassiter Wright III | +6 | $194.699 | $1,168 |
| 2026-04-20 | KUPPUSAMY KARTHIK | +39 | $194.699 | $7,593 |
| 2026-04-20 | DELANEY MARK E | +37 | $194.696 | $7,204 |
| 2026-04-01 | WENTWORTH TIMOTHY C | +198 | - | - |
| 2026-03-09 | WENTWORTH TIMOTHY C | +215 | - | - |
| 2026-03-05 | Doherty Catherine T. | -5,558 | $206.21 | $1,146,115 |
| 2026-03-05 | PREVOZNIK MICHAEL E | -3,878 | $206.21 | $799,682 |
| 2026-03-05 | Plewman Patrick | -2,855 | $206.21 | $588,730 |
| 2026-03-04 | SAMAD SAM | -7,720 | $204.86 | $1,581,519 |
| 2026-03-04 | SAMAD SAM | +13,947 | $204.86 | $2,857,182 |
| 2026-03-04 | Doherty Catherine T. | -5,806 | $204.86 | $1,189,417 |
| 2026-03-04 | Doherty Catherine T. | +11,364 | $204.86 | $2,328,029 |
| 2026-03-04 | DELANEY MARK E | -2,326 | $204.86 | $476,504 |
| 2026-03-04 | DELANEY MARK E | +5,682 | $204.86 | $1,164,015 |
| 2026-03-04 | PREVOZNIK MICHAEL E | -3,354 | $204.86 | $687,100 |
| 2026-03-04 | PREVOZNIK MICHAEL E | +7,232 | $204.86 | $1,481,548 |
| 2026-03-04 | Davis J. E. | -26,414 | $204.86 | $5,411,172 |
| 2026-03-04 | Davis J. E. | +51,652 | $204.86 | $10,581,429 |
| 2026-03-04 | Plewman Patrick | -2,827 | $204.86 | $579,139 |
| 2026-03-04 | Plewman Patrick | +5,682 | $204.86 | $1,164,015 |
| 2026-03-04 | Deppe Michael J | -750 | $204.86 | $153,645 |
| 2026-03-04 | Deppe Michael J | +1,473 | $204.86 | $301,759 |
| 2026-03-04 | KUPPUSAMY KARTHIK | -2,628 | $204.86 | $538,372 |
| 2026-03-04 | KUPPUSAMY KARTHIK | +6,200 | $204.86 | $1,270,132 |
| 2026-03-03 | Doherty Catherine T. | -632 | $207.73 | $131,285 |
| 2026-03-03 | PREVOZNIK MICHAEL E | -526 | $207.73 | $109,266 |
| 2026-03-03 | Plewman Patrick | -410 | $207.73 | $85,169 |
| 2026-03-02 | Doherty Catherine T. | -648 | $204.86 | $132,749 |
| 2026-03-02 | SAMAD SAM | -869 | $204.86 | $178,023 |
| 2026-03-02 | PREVOZNIK MICHAEL E | -288 | $204.86 | $59,000 |
| 2026-03-02 | Davis J. E. | -10,000 | $212.52 | $2,125,200 |
| 2026-03-02 | Davis J. E. | -2,968 | $204.86 | $608,024 |
| 2026-03-02 | Plewman Patrick | -230 | $204.86 | $47,118 |
| 2026-03-02 | KUPPUSAMY KARTHIK | -205 | $204.86 | $41,996 |
| 2026-03-02 | DELANEY MARK E | -188 | $204.86 | $38,514 |
| 2026-03-02 | Deppe Michael J | -88 | $204.86 | $18,028 |
| 2026-02-19 | Doherty Catherine T. | -1,433 | $204.83 | $293,521 |
| 2026-02-19 | Plewman Patrick | -958 | $204.83 | $196,227 |
| 2026-02-19 | PREVOZNIK MICHAEL E | -1,111 | $204.83 | $227,566 |
| 2026-02-18 | DELANEY MARK E | +7,332 | - | - |
| 2026-02-18 | DELANEY MARK E | -230 | $206.99 | $47,608 |
| 2026-02-18 | DELANEY MARK E | -205 | $210.01 | $43,052 |
| 2026-02-18 | DELANEY MARK E | +1,586 | - | - |
| 2026-02-18 | KUPPUSAMY KARTHIK | +9,853 | - | - |
| 2026-02-18 | KUPPUSAMY KARTHIK | +2,135 | - | - |
| 2026-02-18 | KUPPUSAMY KARTHIK | -259 | $206.99 | $53,610 |
| 2026-02-18 | KUPPUSAMY KARTHIK | -252 | $210.01 | $52,923 |
| 2026-02-18 | Deppe Michael J | +1,688 | - | - |
| 2026-02-18 | Deppe Michael J | -99 | $206.99 | $20,492 |
| 2026-02-18 | Deppe Michael J | -83 | $210.01 | $17,431 |
| 2026-02-18 | Deppe Michael J | +366 | - | - |
| 2026-02-18 | SAMAD SAM | +18,303 | - | - |
| 2026-02-18 | SAMAD SAM | -1,010 | $206.99 | $209,060 |
| 2026-02-18 | SAMAD SAM | -855 | $210.01 | $179,559 |
| 2026-02-18 | SAMAD SAM | +3,965 | - | - |
| 2026-02-18 | Davis J. E. | +73,225 | - | - |
| 2026-02-18 | Davis J. E. | -3,788 | $206.99 | $784,078 |
| 2026-02-18 | Davis J. E. | -2,396 | $210.01 | $503,184 |
| 2026-02-18 | Davis J. E. | +15,857 | - | - |
| 2026-02-18 | Doherty Catherine T. | +13,514 | - | - |
| 2026-02-18 | Doherty Catherine T. | -728 | $206.99 | $150,689 |
| 2026-02-18 | Doherty Catherine T. | -433 | $210.01 | $90,934 |
| 2026-02-18 | Doherty Catherine T. | +2,928 | - | - |
| 2026-02-18 | Plewman Patrick | +9,009 | - | - |
| 2026-02-18 | Plewman Patrick | -293 | $206.99 | $60,648 |
| 2026-02-18 | Plewman Patrick | -244 | $210.01 | $51,242 |
| 2026-02-18 | Plewman Patrick | +1,952 | - | - |
| 2026-02-18 | PREVOZNIK MICHAEL E | +9,289 | - | - |
| 2026-02-18 | PREVOZNIK MICHAEL E | -347 | $206.99 | $71,826 |
| 2026-02-18 | PREVOZNIK MICHAEL E | -301 | $210.01 | $63,213 |
| 2026-02-18 | PREVOZNIK MICHAEL E | +2,013 | - | - |
| 2026-02-13 | Doherty Catherine T. | -26,165 | $112.17 | $2,934,928 |
| 2026-02-13 | Doherty Catherine T. | -351 | $209.1024 | $73,395 |
| 2026-02-13 | Doherty Catherine T. | -1,619 | $208.2107 | $337,093 |
| 2026-02-13 | Doherty Catherine T. | -3,500 | $207.0822 | $724,788 |
| 2026-02-13 | Doherty Catherine T. | -10,122 | $206.3706 | $2,088,883 |
| 2026-02-13 | Doherty Catherine T. | -10,573 | $205.2072 | $2,169,656 |
| 2026-02-13 | Doherty Catherine T. | +26,165 | $112.17 | $2,934,928 |
| 2026-02-10 | Plewman Patrick | -5,662 | $121.805 | $689,660 |
| 2026-02-10 | Plewman Patrick | -5,662 | $204 | $1,155,048 |
| 2026-02-10 | Plewman Patrick | +5,662 | $121.805 | $689,660 |
| 2026-01-28 | Plewman Patrick | +48 | $183.512 | $8,809 |
| 2026-01-28 | DELANEY MARK E | +15 | $183.51 | $2,753 |
| 2026-01-28 | KUPPUSAMY KARTHIK | +16 | $183.516 | $2,936 |
| 2026-01-28 | SAMAD SAM | +69 | $183.514 | $12,662 |
| 2026-01-28 | Gregg Vicky B | +67 | $183.513 | $12,295 |
| 2026-01-28 | CARTER ROBERT B | +6 | $183.51 | $1,101 |
| 2026-01-28 | Lassiter Wright III | +7 | $183.51 | $1,285 |
| 2025-11-25 | Davis J. E. | -55,093 | $95.795 | $5,277,634 |
| 2025-11-25 | Davis J. E. | -4,747 | $192.9717 | $916,037 |
| 2025-11-25 | Davis J. E. | -41,004 | $192.2715 | $7,883,901 |
| 2025-11-25 | Davis J. E. | -9,342 | $191.5888 | $1,789,823 |
| 2025-11-25 | Davis J. E. | +55,093 | $95.795 | $5,277,634 |
| 2025-11-25 | Gregg Vicky B | -1,250 | $191.76 | $239,700 |
| 2025-11-18 | DELANEY MARK E | -100 | $143.33 | $14,333 |
| 2025-11-18 | DELANEY MARK E | -7,846 | $144.47 | $1,133,512 |
| 2025-11-18 | DELANEY MARK E | -7,946 | $187.35 | $1,488,683 |
| 2025-11-18 | DELANEY MARK E | +100 | $143.33 | $14,333 |
| 2025-11-18 | DELANEY MARK E | +7,846 | $144.47 | $1,133,512 |
| 2025-11-05 | Davis J. E. | -7,143 | $175.57 | $1,254,097 |
| 2025-10-23 | PFEIFFER GARY M | -4,413 | $190.58 | $841,030 |
| 2025-10-22 | PFEIFFER GARY M | -1,482 | $182.4 | $270,317 |
| 2025-10-21 | SAMAD SAM | +68 | $189.081 | $12,858 |
| 2025-10-21 | Plewman Patrick | +46 | $189.079 | $8,698 |
| 2025-10-21 | KUPPUSAMY KARTHIK | +15 | $189.076 | $2,836 |
| 2025-10-21 | Gregg Vicky B | +70 | $189.082 | $13,236 |
| 2025-10-21 | DELANEY MARK E | +15 | $189.077 | $2,836 |
| 2025-10-21 | CARTER ROBERT B | +6 | $189.089 | $1,135 |